Connor Clark & Lunn Investment Management Ltd. Cuts Stock Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Connor Clark & Lunn Investment Management Ltd. decreased its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 11.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 272,400 shares of the company’s stock after selling 33,659 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in MiMedx Group were worth $1,610,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Isthmus Partners LLC increased its holdings in shares of MiMedx Group by 30.4% in the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after buying an additional 91,714 shares during the last quarter. Blue Trust Inc. bought a new stake in MiMedx Group during the third quarter worth approximately $30,000. Point72 Asset Management L.P. purchased a new stake in MiMedx Group during the second quarter valued at approximately $40,000. Entropy Technologies LP bought a new stake in shares of MiMedx Group in the 3rd quarter valued at approximately $64,000. Finally, Quest Partners LLC purchased a new position in shares of MiMedx Group in the 2nd quarter worth approximately $81,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price target on shares of MiMedx Group in a report on Thursday, August 1st. StockNews.com lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Finally, Craig Hallum cut their price target on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, MiMedx Group currently has an average rating of “Buy” and an average target price of $12.00.

MiMedx Group Stock Down 1.2 %

Shares of MDXG opened at $9.09 on Tuesday. The firm has a fifty day moving average price of $6.66 and a 200-day moving average price of $6.85. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $1.34 billion, a P/E ratio of 16.53 and a beta of 1.94. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $9.49.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.